Intra-tumoral YAP and TAZ heterogeneity drives collective NSCLC invasion that is targeted by SUMOylation inhibitor TAK-981.
Sharma R, Sharma S, Shriwas P, Mehta L, Vu AH, Mouw JK, Koo J, Huang C, Matsuk VY, Tucker-Burden C, Joseph G, Behera M, Sun SY, Roy MA, Gilbert-Ross M, Leal T, Marcus AI, Shanmugam M.
Sharma R, et al. Among authors: sun sy.
iScience. 2024 Oct 11;27(11):111133. doi: 10.1016/j.isci.2024.111133. eCollection 2024 Nov 15.
iScience. 2024.
PMID: 39524367
Free PMC article.